Beneficial effects of intramyocardial mesenchymal stem cells and VEGF165 plasmid injection in rats with furazolidone induced dilated cardiomyopathy. Issue 8 (5th March 2015)

• Record Type: Journal Article
• Authors: Yu, Qin; Fang, Weiyi; Zhu, Ning; Zheng, Xiaoqun; Na, Rongmei; Liu, Baiting; Meng, Lili; Li, Zhu; Li, Qianxiao; Li, Xiaofei
• Is Part Of: Journal of cellular and molecular medicine. Volume 19:Issue 8(2015)
• Page Start: 1868
• Page End: 1876
• Publication Date: 2015-03-05
• Subjects: Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.12558
• Languages: English
• ISSNs: 1582-1838

Abstract

<abstract abstract-type="main" id="jcmm12558-abs-0001"> <title>Abstract</title> <p>To explore the impact of myocardial injection of mesenchymal stem cells (MSCs) and specific recombinant human VEGF<sub>165</sub> (hVEGF<sub>165</sub>) plasmid on collagen remodelling in rats with furazolidone induced dilated cardiomyopathy (DCM). DCM was induced by furazolidone (0.3 mg/bodyweight (g)/day per gavage for 8 weeks). Rats were then divided into four groups: (<italic>i</italic>) PBS group (<italic>n</italic> = 18): rats received equal volume myocardial PBS injection; (<italic>ii</italic>) MSCs group (<italic>n</italic> = 17): 100 μl culture medium containing 10<sup>5</sup> MSCs were injected into four sites of left ventricular free wall (25 μl per site); (<italic>iii</italic>) GENE group (<italic>n</italic> = 18): pCMVen‐MLC2v‐EGFP‐VEGF<sub>165</sub> plasmid [5 × 109 pfu (0.2 ml)] were injected into four sites of left ventricular free wall (0.05 ml per site)] and (<italic>iv</italic>) MSCs+GENE group (<italic>n</italic> = 17): rats received both myocardial MSCs and pCMVen‐MLC2v‐EGFP‐VEGF<sub>165</sub> plasmid injections. After 4 weeks, cardiac function was evaluated by echocardiography. Myocardial mRNA expressions of type I, type III collagen and transforming growth factor (TGF)‐β1 were detected by RT‐PCR. The protein expression of hVEGF<sub>165</sub> was determined by Western blot. Myocardial protein expression of hVEGF<sub>165</sub> was demonstrated in GENE and MSCs+GENE groups. Cardiac function was improved in MSCs, GENE and MSCs+GENE groups. Collagen volume fraction was significantly reduced and myocardial TGF‐β1 mRNA expression significantly down‐regulated in both GENE and MSCs+GENE groups, collagen type I/III ratio reduction was more significant in MSCs+GENE group than in MSCs or GENE group. Myocardial MSCs and hVEGF<sub>165</sub> plasmid injection improves cardiac function possibly through down‐regulating myocardial TGF‐β1 expression and reducing the type I/III collagen ratio in this DCM rat model.</p> </abstract>